The world of baseball is abuzz with controversy as news breaks about potential drug suspensions. But who's in the spotlight this time?
Philadelphia Phillies outfielder Johan Rojas is fighting a potential 80-game ban imposed by Major League Baseball (MLB) due to a suspected failed drug test for performance-enhancing substances. This news, revealed by an anonymous source to The Associated Press on Tuesday, has sent shockwaves through the baseball community.
The source, speaking on the condition of anonymity, disclosed that the positive test result has not been publicly announced yet, which is standard procedure under MLB's drug agreement with the players' association. This agreement mandates that appeals for initial positive tests for performance-enhancing drugs are handled before any public discipline announcement.
Rojas, aged 25, made his MLB debut in 2023, but his recent performance has been underwhelming. He was even dropped from the Dominican Republic's World Baseball Classic roster, as confirmed by team general manager Nelson Cruz on Monday. Last season, Rojas managed a .224 batting average with one home run, 18 RBIs, and 12 stolen bases for the Phillies. His struggles led to a demotion to Triple-A Lehigh Valley on August 1, and he didn't return to the Phillies lineup for the rest of the season. This spring training, Rojas is 1 for 11, indicating a slow start to the season.
In his young career, Rojas has a .252 batting average, with six home runs, 73 RBIs, and an impressive 51 stolen bases over 250 games.
But the story doesn't end with Rojas. And here's where it gets controversial...
Atlanta Braves outfielder Jurickson Profar has been handed a full-season suspension by MLB, effective immediately, following his second positive test for performance-enhancing drugs. Profar's test revealed the presence of exogenous testosterone and its metabolites, meaning testosterone not naturally produced by his body. This second offense resulted in a 162-game suspension.
Profar's case is particularly intriguing. He was an All-Star in 2024 but was suspended for 80 games last year after testing positive for Chorionic Gonadotrophin (hCG), a hormone that boosts testosterone production. At the time, Profar took responsibility, stating he would never knowingly take banned substances. However, this second offense raises questions about the effectiveness of MLB's drug prevention and treatment programs.
The Braves, in a statement, expressed deep disappointment about Profar's failed drug test, emphasizing their commitment to educating players about the program and its consequences. Profar, who returned from his previous suspension on July 2, finished the season with a .245 average, 14 homers, 43 RBIs, and a .787 OPS in 80 games. His performance in 2024 was even more impressive, with a .280 batting average and career highs in homers, RBIs, and OPS.
Profar's recent sports hernia surgery in November, requiring a six-week recovery, has also been a topic of discussion. He has played in four spring training games this year, batting 3 for 10 with three RBIs. The suspension will keep him out of the postseason and the World Baseball Classic, where he was set to represent the Netherlands. Financially, Profar will lose his entire $15 million salary for this year, part of a $42 million, three-year contract through 2027. He had already lost half of his $12 million salary in 2025 due to the initial suspension.
Profar's case is the seventh instance of a player receiving a 162-game suspension for a second performance-enhancing drug offense. This raises the question: Are MLB's drug policies effective, or is there a deeper issue within the league?
What do you think? Are these suspensions fair, or is there room for improvement in MLB's approach to drug testing and prevention? Share your thoughts in the comments below!
